AFT Pharmaceuticals Showcases Multi-Billion-Dollar R&D Pipeline Featuring Three Advanced Breakthrough Therapies

Intravenous Iron Therapy Targets US$7.4 Billion Market Opportunity

AFT Pharmaceuticals’ R&D pipeline includes an intravenous iron therapy designed to overcome limitations of existing iron infusions. This therapy aims to enable patients to receive treatment in a single dose instead of multiple visits, significantly enhancing convenience and patient outcomes. It also offers improved tolerability compared to current options, potentially broadening the patient base eligible for iron replacement therapy. The therapy targets an addressable market estimated at US$7.4 billion.

This development aligns with AFT’s strategic focus on unmet clinical needs, developing or licensing medicines to address them. Iron deficiency anaemia affects millions globally across indications such as post-surgical recovery, chronic kidney disease, and gastrointestinal bleeding. By reducing treatment appointments and enhancing tolerability, AFT’s therapy could expand access for patients who previously struggled with existing infusions. This product exemplifies how AFT leverages R&D capabilities to add value across its therapeutic portfolio.

FDA Tentative Approval for Room-Temperature Stable Cream Marks Third Patented Medicine Milestone

AFT Pharmaceuticals announced that the US FDA granted tentative approval for a room-temperature stable cream formulated to treat Port Wine Stains and Facial Angiofibromas related to Tuberous Sclerosis Complex. This tentative approval for facial angiofibromas is a major regulatory achievement, representing AFT’s third FDA approval for a patented medicine it developed—an unmatched record among New Zealand pharmaceutical companies.

The cream’s room-temperature stability addresses a key limitation of current treatments that require refrigeration and complex handling. This innovation improves accessibility, patient convenience, and clinical utility for both Port Wine Stains and Tuberous Sclerosis Complex facial angiofibromas. The combined market potential for these indications exceeds US$1 billion. This product highlights AFT’s ability to create innovative formulations that overcome existing treatment barriers while generating intellectual property and commercial value globally.

Room-Temperature Storage Technology Expands Market Access for Intravenous Medicines

A major component of AFT’s portfolio is a proprietary technology enabling intravenous medicines, which currently require refrigeration, to be stored at room temperature. This breakthrough tackles significant logistical challenges in pharmaceutical distribution and hospital administration by simplifying storage, transport, and handling in both developed and emerging markets. By converting refrigeration-dependent medicines to room-temperature stable forms, AFT’s technology could greatly expand market accessibility and improve patient outcomes through easier administration.

AFT estimates the initial markets for products utilizing this technology to be worth up to US$6 billion collectively. Its application across multiple intravenous medicine categories positions this as a platform innovation with significant potential value across AFT’s portfolio and future licensing deals. This foundational technology development reflects AFT’s approach to maximizing R&D returns while addressing multiple unmet clinical needs simultaneously.

Infantile Haemangioma Treatment Program Targets Market Over US$1 Billion

AFT is developing a medicine specifically for infantile haemangioma, or strawberry birthmarks, the most common vascular tumors in infants affecting about 3% of children by age one. While many regress naturally, a significant portion require treatment due to visual obstruction, ulceration risk, or functional impairment. Current treatments include corticosteroids, beta-blockers, and surgery, with limited pharmacological options optimized for this condition.

If approved, AFT’s medicine would fulfill an unmet need for targeted pediatric therapy. The company estimates the market potential exceeds US$1 billion, reflecting a large global patient population and demand for improved treatments. This program underscores AFT’s focus on specialized therapeutic areas where its R&D can deliver meaningful clinical benefits and access sizable markets. It exemplifies the company’s strategy to develop medicines addressing suboptimal existing options.

Maxigesic Intravenous Development Drives Strong Licensing and Royalty Revenues

AFT highlighted the commercial success of its R&D projects, notably the intravenous form of its patented Maxigesic pain relief medicine. This product has generated substantial shareholder value, delivering multiple millions in returns from the initial R&D investment.

The company earned US$21 million from licensing intellectual property in markets where it does not operate directly, providing immediate returns and expanding global access. Additionally, AFT received US$5.5 million in royalties from licensee sales, creating ongoing revenue streams. Beyond licensing and royalties, the company has achieved multi-million dollar gross margins from direct sales in markets where it distributes intravenously. This diversified revenue model—combining licensing fees, royalties, and direct sales margins—demonstrates AFT’s ability to maximize R&D investment returns through multiple market access strategies.

AFT’s Two-Decade Growth and Self-Funding Business Model

Over 20 years, AFT Pharmaceuticals has maintained a 17 percent compound annual revenue growth rate, reflecting a successful business model that integrates proprietary intellectual property development with specialty medicine commercialisation across therapeutic categories and geographies. The company’s continuous growth is driven by identifying unmet clinical needs and developing or licensing appropriate medicines, then commercialising them worldwide.

AFT stands out in the pharmaceutical sector by combining IP development and specialty medicine commercialisation while funding growth primarily through internal cash flow. Few companies in New Zealand or Australia operate this dual model and fund R&D without relying heavily on external capital. This self-funding approach is supported by profitable operations, enabling ongoing R&D investment and reducing shareholder dilution compared to firms dependent on external financing.

Global Business Hubs Enable Up to 50 Percent Direct Market Coverage

AFT has established and expanded business hubs across seven key regions: Australia, New Zealand, Singapore, Hong Kong, USA, Canada, and the UK. This network allows direct commercialisation of select R&D products across diverse regulatory and healthcare systems, reducing reliance on external licensees and distributors. The company estimates this strategy enables coverage of up to 50 percent of the global market directly for certain portfolio segments, significantly enhancing its commercial reach.

The hub strategy balances direct access to major pharmaceutical markets with licensing efficiency in less economical regions. These hubs span North America, Western Europe, Asia-Pacific, and other major markets, positioning AFT to serve large developed markets directly while pursuing licensing in smaller or emerging territories. This infrastructure supports commercialisation across over-the-counter, prescription, and hospital channels, providing a competitive advantage for pipeline product launches.

Diversified Portfolio of Patented Medicines, Off-Patent Injectables, and Early-Stage Projects

AFT’s R&D and product portfolio includes eight patented projects featuring proprietary or in-licensed intellectual property. Additionally, it holds 24 off-patent injectable formulations that generate revenue through established channels with lower regulatory risk than new molecular entities. The portfolio also contains early-stage projects offering multiple growth pathways as they progress through development and approval.

This diversified portfolio balances revenue sources and risk profiles. Patented medicines provide premium pricing and IP protection, generating returns via licensing and direct sales. Off-patent injectables offer steady revenue with proven commercial viability and reduced regulatory hurdles. Early-stage projects represent future growth with higher risk but significant upside potential. This balanced approach supports consistent revenue and cash flow, enabling sustained R&D investment and shareholder returns.

Licensing and Out-Licensing Strategy Extends Reach to Over 125 Countries

AFT’s business model extensively employs out-licensing to local partners, expanding product availability across more than 125 countries. This approach monetizes intellectual property and product portfolios in markets without direct operations, generating upfront licensing fees and ongoing royalties as licensees commercialize products. Out-licensing offers capital-efficient market access, allowing AFT to focus direct operations on core markets where it holds competitive advantages.

The company’s presentation highlighted the intravenous Maxigesic formulation’s US$21 million in licensing revenues and US$5.5 million in royalties from out-licensing, validating this strategy’s commercial success. By combining direct commercialisation in major markets with selective out-licensing elsewhere, AFT has built a diversified revenue model maximizing R&D returns. This strategy also reduces capital intensity for international expansion, supporting R&D funding primarily through internal cash flow, as noted by Dr. Atkinson. Licensing and out-licensing remain central to AFT’s plan to broaden proprietary medicine markets while focusing direct efforts where competitive advantage is strongest.